Insomnia
We conducted a 30-day study with adults who self-reported sleep difficulties and after using Modius Sleep we found that:
95% of participants improved their overall Sleep Score;
85% were more satisfied with their sleep pattern;
75% reported positive impact on their daily functioning.
A statistically significant reduction in mean Insomnia Severity Index (ISI) score from 15.7 (moderate insomnia) at baseline to 8.15 (sub-threshold insomnia) after 14 days of CES treatment was observed. ISI score reduced by 7.55 (i.e., 48% reduction).
* BMJ Journals: Mckeown J, Goothy SSK, P050 Modulation of sleep using electrical vestibular nerve stimulation prior to sleep onset.
Anxiety
A study in vistibular neurostimulation generated a HAM-A score reduced by 17.46 (i.e., 71% reduction).
A statistically significant reduction in mean Hamilton Anxiety Rating Scale (HAM-A) score from 24.55 (mild to moderate anxiety) at baseline to 7.09 (mild anxiety) after up to 42 days of treatment.
Type 2 Diabetes
In a 16-week study with type 2 diabetic patients, our Vestal DM technology demonstrated a 0.4% reduction in HbA1c.
We are further investigating the impact of our technology on type 2 diabetes in a 6-month global clinical trial. Data will be made available upon the completion of this trial.
Obesity
In a 12-week study with overweight patients, our Vestal technology demonstrated a 2.1kg reduction in body weight (i.e., 2% reduction in body weight).
We are further investigating the impact of our technology on obesity in a 6-month global clinical trial. Data will be made available upon the completion of this trial.
Current Clinical Trials
Adults with Type 2 Diabetes
Electrical vestibular nerve stimulation (VeNS) compared to sham control as a means of improving glycemic control in adults with Type 2 Diabetes mellitus
Primary Outcomes: HbA1c reduction
Location: University College Dublin, Ireland
Dates: 2021 – 2023
Apply NowPrimary Outcomes: HbA1c reduction
Location: Nothern California Medical Research Centre
Dates: 2021 – 2023
Apply NowPrimary Outcomes: HbA1c reduction
Location: Oviedo Medical Research, Orlando Florida
Dates: 2021 – 2023
Apply NowPrimary Outcomes: HbA1c reduction
Location: Charlottesville Medical Research, Virginia
Dates: 2021 – 2023
Apply NowPrimary Outcomes: HbA1c reduction
Locations: The Exercise and Physical Activity Resource Center (EPARC), San Diego
Dates: 2021 – 2023
Apply NowType 2 Diabetes Weight Loss
Weight management study for individuals with Type 2 Diabetes taking insulin
Primary Outcomes: Weight loss & reduced HbA1c
Locations: Belfast, Northern Ireland
Dates: 2022
Apply NowAnxiety
Electrical vestibular nerve stimulation (VeNS) as a management device for anxiety
Primary Outcomes: Reduced stress & anxiety
Locations: Belfast, Northern Ireland
Dates: 2022
Apply NowInsomnia
Electrical vestibular nerve stimulation (VeNS) as a management device for insomnia
Primary Outcomes: Improved sleep & fatigue
Locations: Ulster University, Coleraine, Northern Ireland
Dates: 2022
Apply Now